Replies to post #540 on Revance Therapeutics Inc (RVNC)

[jmkobers]

<<Most likely, EOLS will settle on a price comparable to Dysport and Xeomin—i.e. a modest discount to Botox.>>


Why wouldn't a new player, entering an entrenched market, try to disrupt things by significantly undercutting price? Would you have had similar verbiage after Amphastar received approval for Enoxaparin?

[jmkobers]

<<Most likely, EOLS will settle on a price comparable to Dysport and Xeomin—i.e. a modest discount to Botox.

All told, I don’t expect EOLS’ launch to have a material effect on US pricing. >>


25% isn't modest, eh?